UBS Group
IBO

UBS Group’s Impact BioMedical IBO Stock Holding History

UBS Group’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1K Sell
190
-2,379
-93% -$17.8K ﹤0.01% 9627
2026
Q1 		$19.4K Buy
2,569
+2,397
+1,394% +$15.1K ﹤0.01% 7952
2025
Q4 		$1.1K Sell
172
-1,420
-89% -$9.48K ﹤0.01% 9705
2025
Q3 		$13.4K Sell
1,592
-1,556
-49% -$12.4K ﹤0.01% 8401
2025
Q2 		$25.7K Buy
3,148
+1,867
+146% +$13.2K ﹤0.01% 8282
2025
Q1 		$14.1K Buy
1,281
+944
+280% +$20.6K ﹤0.01% 8444
2024
Q4 		$6.16K Buy
+337
New +$8.82K ﹤0.01% 8588
2024
Q3 		– Hold
0
– – – 9381

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's IBO Position: Q2 2026 in Review

UBS Group reduced its Impact BioMedical (IBO) stake by 93% in Q2 2026, selling an estimated $17.8K and leaving 190 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #9627.

UBS Group first reported a position in IBO in Q4 2024 and has held it in 7 quarters since. The position peaked at $25.7K in Q2 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

  • UBS Group held 190 shares of Impact BioMedical worth $1.1K as of Q2 2026.
  • UBS Group sold 2,379 Impact BioMedical shares in Q2 2026, an estimated $17.8K.
  • Impact BioMedical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9627 holding.
  • UBS Group first reported a position in Impact BioMedical in Q4 2024 and has held it in 7 quarters since.
  • UBS Group's Impact BioMedical position peaked at $25.7K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.